C12N 2760/16041
Use of virus, viral particle or viral elements as a vector
C12N2760/16041 (Use of virus, viral particle or viral elements as a vector) appears on 24 US grants and 45 published applications in this corpus.
Search patents in C12N- Granted patents
- 24
- Published applications
- 45
- Assignees
- 24
- Inventors
- 69
- Latest grant
- 24 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 3 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 2 | 0 |
| 2010 | 0 | 1 |
| 2011 | 1 | 2 |
| 2012 | 0 | 1 |
| 2013 | 0 | 2 |
| 2014 | 3 | 2 |
| 2015 | 1 | 2 |
| 2016 | 1 | 4 |
| 2017 | 1 | 2 |
| 2018 | 1 | 3 |
| 2019 | 4 | 3 |
| 2020 | 1 | 4 |
| 2021 | 1 | 2 |
| 2022 | 0 | 2 |
| 2023 | 2 | 0 |
| 2024 | 2 | 3 |
| 2025 | 1 | 3 |
| 2026 | 1 | 2 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2760/16043Viral genome or elements thereof as genetic vectorIndexing code17
- C12N 2760/16042Virus or viral particle as vehicleIndexing code1
- C12N 2760/16044Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2760/16045Special targeting system for viral vectorsIndexing code0
Recent patents
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes24 Feb 2026US 12,559,717 B2The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes12 Aug 2025US 12,385,010 B2The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes24 Dec 2024US 12,173,314 B2The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes8 Oct 2024US 12,110,504 B2The Board of Trustees of the Leland Stanford Junior University
- Vaccines for human papilloma virus and methods for using the same19 Dec 2023US 11,844,830 B2Inovio Pharmaceuticals, Inc.
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes4 Jun 2026US 2026/0152720 A1The Board of Trustees of the Leland Stanford Junior University
- Neddylation-activating enzyme inhibitors as viral sensitizers and uses thereof15 Jan 2026US 2026/0015592 A1Ottawa Hospital Research Institute
- Non-toxic destruction of cancer cells using viral vectored injections20 Nov 2025US 2025/0352628 A1
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes14 Aug 2025US 2025/0257319 A1The Board of Trustees of the Leland Stanford Junior University
- Gene therapy for recessive dystrophic epidermolysis bullosa using genetically corrected autologous keratinocytes6 Mar 2025US 2025/0075178 A1The Board of Trustees of the Leland Stanford Junior University
Most cited
By later US patents
- Methods of use of viral vectors to deliver antigen to dendritic cells43US 6,300,090 B1The Rockefeller University · 2001
- Recombinant influenza vectors with tandem transcription units41US 7,968,101 B2Wisconsin Alumni Research Foundation · 2011
- Viruses encoding mutant membrane protein33US 7,588,769 B2Wisconsin Alumni Research Foundation · 2009
- Methods of use of viral vectors to deliver antigen to dendritic cells22US 6,455,299 B1The Rockefeller University · 2002
- Recombinant influenza vectors with tandem transcription units17US 8,877,209 B2Wisconsin Alumni Research Foundation · 2014